Sugi Predict

Sugi Predict / Compounds / SCHEMBL1462541

SCHEMBL1462541

SCHEMBL1462541

CCN(CC=O)C(=O)OC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA14 Q9ULX7 2/20 0.37
▸ HDAC6 Q9UBN7 2/20 0.36
▸ HDAC1 Q13547 2/20 0.34
▸ HDAC2 Q92769 2/20 0.34
▸ NFKB1 P19838 1/20 0.34
▸ NFKB2 Q00653 1/20 0.34
▸ RELA Q04206 1/20 0.34
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ CTSK P43235 1/20 0.33
▸ HDAC3 O15379 1/20 0.32
▸ NCOR2 Q9Y618 1/20 0.32
▸ NAMPT P43490 1/20 0.32
▸ CA12 O43570 1/20 0.31
▸ CA1 P00915 1/20 0.31
▸ CA7 P43166 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL111602 0.90 CA14 (0.40) CA14HDAC6HDAC1HDAC2NFKB1
SCHEMBL28350992 0.85 CA14 (0.37) CA14HDAC6HDAC1HDAC2NFKB1
SCHEMBL1962792 0.83 MEN1 (0.45) CA14HDAC6HDAC1HDAC2NFKB1
SCHEMBL3178526 0.83 ALDH1A1 (0.38) CA14HDAC6HDAC1HDAC2NFKB1
SCHEMBL20018290 0.83 CA14 (0.36) CA14HDAC6HDAC1HDAC2NFKB1
SCHEMBL3019714 0.82 CA14 (0.43) CA14HDAC6HDAC1HDAC2NFKB1
SCHEMBL24714957 0.81 CA14 (0.39) CA14HDAC6HDAC1HDAC2NFKB1
SCHEMBL376711 0.81 ALDH1A1 (0.37) CA14HDAC6HDAC1HDAC2NFKB1
SCHEMBL12327588 0.81 HDAC6 (0.37) CA14HDAC6HDAC1HDAC2NFKB1
SCHEMBL14175258 0.81 HDAC6 (0.41) CA14HDAC6HDAC1HDAC2NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503463-B2 Aliphatic acid amide derivative Sumitomo Pharma Co., Ltd. (JP) 2025-12-23 — — US disclosed
US-12473295-B2 Substituted straight chain spiro derivatives JANSSEN PHARMACEUTICA NV (BE) 2025-11-18 — — US disclosed
EP-4082616-B1 ALIPHATIC ACID AMIDE DERIVATIVE SUMITOMO PHARMA CO LTD (JP) 2025-09-03 — — EP disclosed
US-20240166693-A1 METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 Design Therapeutics, Inc. 2024-05-23 — — US disclosed
CN-117279636-A Methods and compounds for modulating myotonic muscular dystrophy type 1 设计治疗公司 2023-12-22 — — CN disclosed
US-11827597-B2 Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation INNATE TUMOR IMMUNITY, INC. (US) 2023-11-28 — — US disclosed
US-11827597-B2 Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation INNATE TUMOR IMMUNITY, INC. (US) 2023-11-28 — — US disclosed
US-11827597-B2 Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation INNATE TUMOR IMMUNITY, INC. (US) 2023-11-28 — — US disclosed
EP-4259133-A1 METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 Design Therapeutics, Inc. (US) 2023-10-18 — — EP disclosed
US-20230142285-A1 SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2023-05-11 — — US disclosed
EP-2374798-B1 Benzazepine derivatives useful as vasopressin antagonists OTSUKA PHARMA CO LTD (JP) 2013-09-04 — — EP disclosed
EP-2374797-A1 Benzazepine derivatives useful as vasopressin antagonists OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-10-12 — — EP disclosed
EP-2374798-A1 Benzazepine derivatives useful as vasopressin antagonists OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-10-12 — — EP disclosed
US-20110071084-A1 BENZAZEPINE DERIVATIVES USEFUL AS VASOPRESSIN ANTAGONISTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-03-24 — — US disclosed
EP-2170831-A1 BENZAZEPINE DERIVATIVES USEFUL AS VASOPRESSIN ANTAGONISTS Otsuka Pharmaceutical Co., Ltd. (JP) 2010-04-07 — — EP disclosed
WO-2009001968-A1 BENZAZEPINE DERIVATIVES USEFUL AS VASOPRESSIN ANTAGONISTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-12-31 — — WO disclosed
EP-1194152-A4 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO INC (US) 2002-11-06 — — EP disclosed
EP-1194152-A1 SRC KINASE INHIBITOR COMPOUNDS Merck & Co., Inc. (US) 2002-04-10 — — EP disclosed
US-6316444-B1 SRC kinase inhibitor compounds MERCK & CO., INC. 2001-11-13 — — US disclosed
WO-2001000214-A1 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO., INC. (US) 2001-01-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240166693-A1 METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 MTPN, DMPK, MBNL1 CA14 4859/4885HDAC6 1311/4885HDAC1 658/4885
US-12473295-B2 Substituted straight chain spiro derivatives MLLT1, MEN1, MLLT3 CA14 4838/4885HDAC6 1557/4885HDAC1 1241/4885
US-20110071084-A1 BENZAZEPINE DERIVATIVES USEFUL AS VASOPRESSIN ANTAGONISTS AVPR2, AVPR1B, AVPR1A CA14 2908/4885HDAC6 1390/4885HDAC1 406/4885
US-11827597-B2 Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation NLRP3, NOD1, NLRP1 CA14 4819/4885HDAC6 2270/4885HDAC1 2239/4885
US-12503463-B2 Aliphatic acid amide derivative HTR2A, HTR1A, HTR7 CA14 4756/4885HDAC6 433/4885HDAC1 382/4885
US-20230142285-A1 SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES MLLT1, MEN1, MLLT3 CA14 4838/4885HDAC6 1557/4885HDAC1 1241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.